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Background: Bipolar affective disorder (BP) is a common, highly heritable psychiatric disorder characterized by periods
of depression and mania. Using dense SNP genotype data, we characterized CNVs in 388 members of an Old Order
Amish Pedigree with bipolar disorder. We identified CNV regions arising from common ancestral mutations by utilizing
the pedigree information. By combining this analysis with whole genome sequence data in the same individuals, we
also explored the role of compound heterozygosity.
Results: Here we describe 541 inherited CNV regions, of which 268 are rare in a control population of European origin
but present in a large number of Amish individuals. In addition, we highlight a set of CNVs found at higher frequencies
in BP individuals, and within genes known to play a role in human development and disease. As in prior reports, we
find no evidence for an increased burden of CNVs in BP individuals, but we report a trend towards a higher burden of
CNVs in known Mendelian disease loci in bipolar individuals (BPI and BPII, p = 0.06).
Conclusions: We conclude that CNVs may be contributing factors in the phenotypic presentation of mood disorders and
co-morbid medical conditions in this family. These results reinforce the hypothesis of a complex genetic architecture
underlying BP disorder, and suggest that the role of CNVs should continue to be investigated in BP data sets.
Keywords: CNV, Bipolar disorder, Family based studies, Mendelian disease genes, Genetics lociBackground
Bipolar affective disorder (BP) is a serious mental dis-
order characterized by periodic changes in mood, energy
and activity levels alternating between episodes of de-
pression and mania [1]. The lifetime prevalence of BP
type I (BPI) and type II (BPII) is 2.1% in the United
States [2] and the age of onset is early, at 18–19.5 years
old [3], making BP responsible for the loss of more
disability-adjusted life-years than all forms of cancer [4]
and consequently it is a major public health concern [5].
As with many complex disorders, the underlying eti-
ology of BP is unknown, but is hypothesized to be the
result of multiple gene-gene and gene-environment in-
teractions [6]. Epidemiological studies using twin data* Correspondence: bucan@upenn.edu
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unless otherwise stated.show that BP has heritability estimates ranging from 62-
89% [7,8], although the mode of inheritance is complex.
Common genetic factors have been shown to contribute
substantially to susceptibility for bipolar disorder, with a
strong polygenic contribution [9]. Several potential BP
candidate genes have been described [10], but findings
are inconsistent and the role of specific genes in BP is
currently undetermined.
Copy number polymorphisms (CNVs) are a common
class of genetic variation in the human genome [11-14],
and can be readily detected using intensity data from
genome-wide SNP arrays. Like single-nucleotide polymor-
phisms (SNPs), CNVs can affect gene expression, either by
encompassing genes or regulatory elements. Large, cyto-
genetically detectable chromosomal rearrangements, such
as aneuploidy, have been historically linked to human dis-
ease [15]. Studies of several genomic disorders, associated
with inherited or sporadic genomic anomalies which arel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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conventional cytogenetic methods, revealed that deletions
and duplications encompassing several genes may lead to
complex and highly pleiotropic clinical syndromes [16].
Several systematic surveys of copy number variation using
Comparative Genomic Hybridization (CGH) and high-
density SNP arrays revealed a large number of benign dele-
tions and duplications across the genome, but also revealed
the role of a large number of rare potentially pathogenic
CNVs in neurodevelopmental and psychiatric diseases, par-
ticularly in Autism Spectrum Disorder and Schizophrenia
[17]. In Autism Spectrum Disorder, CNVs were found in a
number of chromosomal regions [18], and the burden of
rare and de novo CNVs was enriched in affected individuals
compared to controls and their unaffected siblings [19].
Similarly, several large, rare CNVs have been associated with
schizophrenia [20,21]. Among these CNVs several have been
observed at elevated rates in multiple neurodevelopmental
and psychiatric disorders [22,23].
Both linkage and candidate gene analyses, as well as
genome-wide association studies, indicate a shared genetic
architecture and an overlap of susceptibility between BP
and schizophrenia [24]. However, compared to studies
conducted on ASD and schizophrenia, there are far fewer
examples of CNVs associated with BP [25]. An analysis of
1001 cases and 1034 controls reported an increased bur-
den of singleton CNVs in early onset bipolar cases [26].
Also, in an independent study of 788 trios, frequencies of
de novo CNVs were significantly higher in bipolar disorder
as compared to controls, but not as high as in schizo-
phrenia [27]. However, a study using Welcome Trust
Case Control Consortium (WTCCC) data found no evi-
dence for an elevated burden of CNVs in bipolar individuals
(n = 1697) compared to controls (n = 2806), although the
burden was found to be elevated in schizophrenia [28]. The
same authors recently published the most comprehensive
analysis of CNVs in the WTCCC revealing a significantly
lower rate of rare very large CNVs (>1 Mb) in patients with
bipolar disorder (n = 1,650) compared to reference individ-
uals without psychiatric disorder (n = 10,259) [29]. Al-
though the authors state that this result needs to be verified
in larger datasets, they propose that a lower CNV burden
may underlie differences in the presentation of clinical
phenotype between bipolar disorder and schizophrenia. In
addition, recent research suggests that de novo CNVs may
play a smaller role in BP compared to schizophrenia [30],
but the role of inherited CNVs remains uncertain.
The Old Order Amish are a founder population origin-
ating in middle Europe. Since 1964, when Victor McKusic
and colleagues described the benefits from medical genet-
ics studies in the Amish [31], a large number of Mendelian
disorders have been described in this population [32].
More recently, next generation sequencing studies of neu-
rodevelopmental and psychiatric disorders in the Amishprovide a unique opportunity to address the role of rarer
forms of genetic variation [33,34]. However, these recent
studies focus on the role of single nucleotide variants
(SNVs). Apart from a handful of gene deletions associated
with Mendelian disease [32], and 50 CNV regions identi-
fied in a subset of individuals from the Old Order Amish
pedigree with bipolar disorder [35], global analysis of copy
number variation has not been systematically carried out
in this genetic isolate.
The aim of the present study was to investigate CNVs in
the extended Old Order Amish pedigree with bipolar dis-
order, and compare these CNVs with CNVs detected in a
large collection of unrelated control subjects to identify
deletions and duplications private to this family. Also, we
compared burden and frequency of CNVs in family mem-
bers with affective disorders (BPI, BPII and MDD-R) with
their unaffected relatives to identify CNVs potentially con-
tributing to the locus and allele heterogeneity of bipolar
disorder. Our systematic analysis revealed 67 rare and
moderately rare CNVs encompassing Mendelian disease
genes that may contribute to the complex and pleiotropic
manifestation of mental illness in this founder population.
Results
Overall strategy
To characterize structural variants in 388 members of a
large multigenerational Old Order Amish pedigree with
bipolar disorder, we used dense SNP genotype data gen-
erated using the Illumina Omni 2.5 M platform [33]. We
also performed CNV analysis on 2,156 Age-related Eye
Disease Study (AREDS) control subjects (1,897 with
European ethnicity) genotyped using the same SNP plat-
form. A flowchart (Figure 1) outlines the quality control
and analysis pipeline employed to address: a) differences
in the allele frequency of CNVs in this genetic isolate
compared to a large sample of subjects of European ori-
gin; b) the role of CNVs in susceptibility to bipolar ill-
ness in this large pedigree; c) an estimate of the total per
genome (or person) burden of CNVs, including CNVs
that encompass known disease loci.
A catalog of inherited CNVs in an Amish pedigree
segregating bipolar disorder
As part of our genetic study of bipolar disorder in the Old
Order Amish, we analyzed genome-wide SNP genotype
data using the Penn CNV algorithm [36] to identify CNVs.
We examined the breakpoints of all CNVs (n = 18,986)
and clustered groups of CNVs that have arisen from com-
mon ancestral mutations (see Methods) into CNV regions
(n = 561). Using the pedigree relationships, we classified
all regions as either ‘inherited’ (shown to pass from parent
to child), or of ‘unknown origin’ (not seen in either par-
ent). To avoid possible technical artifacts in the analysis,
we focused on the high quality, inherited CNVs observed
Figure 1 Flowchart outlining the quality control and analysis pipeline of this study. SNP data from the control and Old Order Amish populations
was used to call CNVs using the PennCNV program. The pedigree structure in the Amish allowed family based calls to be made, and the CNV
frequency in the control data allowed us to determine whether the Amish CNV calls were common, rare, or exclusive to the Amish population.
We sought to determine CNVs in bipolar individuals, burden in individuals, and CNVs in disease loci. In addition, we utilized the whole genome
sequence data to find CNVs and SNPs within the same gene in the same individual.
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These variants are less likely to represent false positives in
computational prediction or rearrangements that arose
during culturing of lymphoblastoid cell lines [37]. Further-
more, in a large pedigree with an excess of bipolar dis-
order, we expect that the causal genetic variants will be
inherited, rather than de novo. Of 541 inherited CNV re-
gions identified by the analysis of 328 family members (a
subset that contains both parent and child information),
33 overlap with 50 regions previously identified in a small
scale study of the core family, i.e. 50 family members [35].
Eight CNV regions (four which are exonic, one which is
intronic, and three which are intergenic) were detected on
Chromosome X (Additional file 1: Table S2).
Among detected inherited CNV regions, the largest
category consisted of common CNVs (present in more
than 5% of controls) found throughout the large multi-
generational Amish pedigree. In addition we detected
104 moderately rare (present in less than 5% of controls)
and 139 rare (present in less than 1% of controls) CNV
regions in subjects, as well as 129 ‘exclusive’ regions that
were not present in any controls. Of these exclusive re-
gions, 36 are deletions and 93 are duplications, and 99
regions include genes (Figure 2, created using Circos
[38]). These ‘exclusive’ variants form a key part of thegenomic architecture of this pedigree, and could play a
role in phenotypic presentation. To illustrate the fre-
quency of a CNV in the pedigree, CNV counts are pre-
sented for nuclear families only in which the CNV is
present, and only for those individuals with bipolar or
well phenotypes; individuals with unknown or other
phenotypes are excluded. They include a 26 kb duplica-
tion on 13q24, present in 109 Amish individuals (af-
fected 23/86, 26.4%; unaffected 66/232, 28.4%), which
encompasses the entire SRY (sex determining region Y)-
box 1 (SOX1) gene; a 24 kb deletion on 5q33.1, found in
48 individuals (affected 8/38, 21.1%; unaffected 29/79,
36.7%), in an intergenic region upstream of both coiled-
coil domain containing 69 (CCDC69) and GM2 ganglio-
side activator (GM2A); and a 10 kb deletion on
12q21.31, found in 33 individuals (affected 9/25, 36.0%;
unaffected 19/51, 37.3%), located downstream of solute
carrier family 6, member 15 (SLC6A15).
We compared the total number, average size, and burden
per individual of CNVs in a) all family members (n = 375),
b) subjects with bipolar disorder (n = 77), and unaffected
Amish and control individuals (Amish n = 234, controls
n = 1897) (Table 1). Analysis was performed on copy
number losses (deletions) and gains (duplications) sep-
arately. Overall number of detected deletions and
Figure 2 Location of CNV Regions, burden of rare CNVs, and disease genes. CNV regions are shown as red and green lines (green: heterozygous
duplication, dark green: homozygous duplication, red: heterozygous deletion, dark red: homozygous deletion). Stacked histogram bars represent the location
of specific rare CNVs, and the number, split by phenotype (green background: duplications, red background: deletions; dark grey: bipolar, mid-grey: unknown,
light grey: unaffected). Inner line plot (blue) shows location and number of disease genes. Genes of interest are labeled around the outside of the plot.
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those detected in the control subjects.
CNVs and disease association
No individual CNV segregated fully with bipolar disorder.
Analysis of CNV data in the linkage regions previously re-
ported [33] identified a single duplication event in the 7q21
region. The 95 kb duplication localizes upstream of themaximum LOD score marker D7S518. We confirmed in-
heritance of the CNV on the 4-4-1-4 haplotype (D7S2431-
D7S554-D7S518-D7S2509). The duplication spans the first
exon of the collagen, type XXVI, alpha 1 (COL26A1) gene.
COL26A1 has yet to be functionally characterized, with a
possible role in aspirin-intolerant asthma [39].
Burden analysis of CNV regions in genes in the Amish
shows a trend towards an increased number of these
Table 1 Summary of CNV calls for the Old Order Amish (n = 375) and controls (n = 1897)
Total Deletions Duplications
Amish CNVs Amish Inherited CNVs Controls Amish CNVs Amish inherited CNVs Controls Amish CNVs Amish inherited CNVs Controls
Total Number All Samples 18986 6345 77205 10942 4154 51138 8044 2191 26067
Affected 3844 1380 - 2216 905 - 1628 475 -
Unaffected 12191 3962 - 6922 2581 - 5269 1381 -
Average Size (bp) All Samples 36123 42064 29697 31124 32701 23768 42924 59815 41328
Affected 41123 44572 - 39802 33575 - 42921 65523 -
Unaffected 34363 39932 - 29072 32093 - 41315 54581 -
Burden
(per individual)
All Samples 50.6 23.2 40.7 29.2 15.2 27.0 21.6 8.2 13.7
Affected 49.9 23.4 - 28.8 15.3 - 21.1 8.1 -
Unaffected 52.1 23.7 - 29.6 15.5 - 22.5 8.3 -
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BPII), although this does not reach significance (narrow
burden: 17.3, unaffected burden: 15.6, p = 0.11) (Table 2).
We identified three rare deletions in KCNJ6, UNC13C,
OTOL1 and 7 rare duplications in CNTNAP2/MIR548F3,
CORO7/VASN, DTNB, EMID2, KCNF1, PDPR and
SGTA/THOP1 that are present in children with bipolar
disorder (and their parents). In addition, we find other
rare CNVs in genes that are present frequently in individ-
uals with bipolar disorder (Table 3). Association analysis
for all CNV regions was performed using two different
methods: a) FBAT [40] and b) EMMAX [41], although no
CNV was found to be significantly associated with BP fol-
lowing correction for multiple testing. We found no over-
all enrichment of large inherited CNVs in affected
individuals, although 7 large, rare, CNVs in genes oc-
curred more frequently in subjects with bipolar disorder
than unaffected family members and control subjects.
One of the largest rare genic CNVs is the previously re-
ported 150 kb deletion in the 15q11 region, which encom-
passes the entire Prader-Willi region non-protein coding
RNA 2 (PWRN2) gene [35]. The deletion is present in 15
families, is found on two haplotypes (D15S817-D15S1021-
D15S128: 3-6-3 and 3-5-3) and is widely spread through-
out the pedigree; 20/32 (62.5%) of those with bipolar dis-
order in these carrier families have the CNV, compared to
28/52 (53.8%) of well individuals.
Next, we focused on the analysis of CNVs encompass-
ing known disease genes. It has been suggested that het-
erozygosity for several mutations in Mendelian disease
genes may lead to complex disease risk, such as behav-
ioral anomalies in neurodevelopmental and psychiatric
disorders [63]. To ask if CNVs in disease genes may con-
tribute to the allelic architecture in the Amish family
segregating bipolar disorder, we mapped known disease
loci with respect to CNV breakpoints. Specifically, weTable 2 Burden analysis of CNV Regions reveals a higher
number of CNVs in genes in individuals with narrow
bipolar phenotype (BPI and BPII)
Unaffected Broad Narrow
No. All CNVs 28.1 28.7 29.5
P vs unaffected - 0.39 0.26
No. All CNVs in genes 15.6 16.8 17.3
P vs unaffected - 0.16 0.11
No. Rare CNVs in genes 9.7 11.0 11.3
P vs unaffected - 0.12 0.09
No. CNVs in disease genes 4.8 5.5 5.7
P vs unaffected - 0.11 0.06
No. Rare CNVs in disease genes 4.0 4.8 5.0
P vs unaffected - 0.07 0.06
A trend towards an increased number of CNVs in disease genes in individuals
with narrow bipolar phenotype is also reported.utilized the known disease causing variants (classed ‘DM’
in HGMD) from the Human Gene Mutation Database to
define 3457 genes associated with disease. We identified
81 CNV regions that overlap with genes with known dis-
ease causing mutations (Additional file 1: Table S3). Of
these, 27 CNV regions are specific to the Amish pedigree,
and 40 are rare (<5%) in the control population. Interest-
ingly, the number of CNV regions that encompass disease
genes shows a trend towards an increased burden in bipo-
lar narrow phenotype individuals (narrow phenotype bur-
den: 5.7, unaffected burden 4.8, p = 0.06), and this is also
true for rare (including Amish specific) CNVs encompass-
ing disease genes (narrow phenotype burden: 5.0, un-
affected burden 4.0, p = 0.06) (Table 2).
In particular, we explored the transmission (from par-
ent to child) for rare CNV deletions in disease genes.
Additional file 1: Table S4 details the 12 CNV deletions
found in these genes, many of which have a behavioral
disease phenotype (Parkinson disease, Autism Spectrum
Disorder, Intellectual disability). Additional file 1: Figure
S2 displays the extensive genetic heterogeneity within
this founder pedigree, focusing on the CNVs in these 11
genes. Different branches of the pedigree carry different
CNVs, with some nuclear families carrying up to 5 rare
deletions in a known disease associated gene. In
addition, we find a previously identified schizophrenia
associated CNV (17q12del) [64] in an individual with a
BPII phenotype. It is striking that in this individual this
CNV maps in the vicinity of a recombination site on the
paternal chromosome. These results together provide
evidence for a complex role of CNVs in the phenotypic
presentation within this family.
Within this set of disease genes, we found an Amish
exclusive duplication in the HOXD cluster, present in 36
families. Of those with bipolar disorder in these carrier
families 15/54 (28%) have the CNV, compared to around
24/144 (17%) of well individuals. Our analysis also de-
tected three CNVs in genes previously linked to reces-
sive disease in the Plain populations (CNTNAP2: [65];
ADAMTS10, CLCNKB: [32]). These include a rare in-
tronic heterozygous duplication (present in two individ-
uals, including one affected) in contactin associated
protein-like 2 (CNTNAP2), a gene associated with aut-
ism spectrum disorder. In addition, four individuals (one
affected) have an exonic heterozygous deletion not
found in controls in ADAM metallopeptidase with
thrombospondin type 1 motif (ADAMTS10), a candidate
gene for Weill-Marchesani syndrome. Lastly, 12 individ-
uals (four affected) were found to have an exonic hetero-
zygous duplication of the chloride channel, voltage-
sensitive Kb (CLCNKB), variants in which are associated
with essential hypertension.
The availability of a combined dense genotype and
whole genome sequence for 30 parent child trios [33],
Table 3 CNVs within genes










Predicted effect FBAT EMMAX Previous disease
associations for gene
1p36.21 13171723 13218942 31 47220 0&1 LOC440563 Rare 38 13 15 Gene del 1 0.1887
1q22 155152205 155162067 22 13287 3 MUC1, TRIM46 Amish
specific
28 13 32 Partial gene dup 0.0711 0.1535 Kidney disease [42]
1q24.1 165644865 165649715 9 4851 1 ALDH9A1 Very rare 17 7 12 Exonic del 1 0.1434






45 15 32 Gene dup 0.4122 0.9834 Limb and genital
abnormalities [43,44]
2q37.3 241500674 241516094 20 24920 3 DUSP28, RNPEPL1 Very rare 74 13 43 Partial gene dup 0.4226 0.3229
2q37.3 241482099 241516094 20 24920 3 ANKMY1, DUSP28,
RNPEPL1
Very rare 31 7 23 Partial gene dup for
ANKMY1 and RNPEPL1,
gene dup for DUSP28
0.0007 0.3229
3p21.2 51989546 51995419 11 10143 3 GPR62, PCBP4 Amish
specific
72 17 47 Partial gene dup 0.0412 0.0238
3p25.3 11411823 11414339 5 2517 0&1 ATG7 Rare 46 13 24 Intronic del 0.7557 0.7020 Frontotemporal
dementia, Parkinsons
disease [45]
3q29 193136358 193140348 9 3991 0&1 ATP13A4 Rare 41 9 18 Intronic del 0.7389 0.2519 Autism [46]
4q22.1 91907363 91913329 16 10710 1 FAM190A Amish
Specific
34 6 21 Intronic del 0.0099 0.0794





79 17 36 Partial gene dup for LTC4S
and SQSTM1, gene dup for
MGAT4B and MIR1229
0.6641 0.0973 Venous thromboembolism
and ischaemic stroke [47],
Paget disease of bone [48]




61 14 36 Gene dup 0.2513 0.0973 Venous thromboembolism
and ischaemic stroke [47]
6p21.32 32610719 32614917 10 4199 1 HLA-DQA1 Rare 25 7 13 Exonic del 1 0.0574
6p25.3 1612234 1620037 15 9536 3 FOXC1 Very rare 47 14 23 Exonic dup 1 0.5815 Axenfeld-Rieger
anomaly [49]
6q26 163041460 163139315 64 99376 1 PARK2 Very rare 21 5 11 Exonic del 0.5637 0.5534 Parkinsons disease [50],
Autism [51]
7q22.1 100968058 101063059 159 183210 3 EMID2 Rare 100 25 38 Exonic dup 0.0330 0.7031
7q36.1 149461487 149516968 67 55482 3 SSPO, ZNF467 Amish
specific
154 39 68 Partial gene dup 0.8907 0.1100




112 20 59 Partial gene dup for
FAM160B2 and HR, gene
dup for NUDT18
0.0284 0.9422 Alopecia universalis [52],
Congenital Atrichia [53]













Table 3 CNVs within genes (Continued)
8p22 15419777 15432653 24 21108 1 TUSC3 Very rare 19 3 7 Intronic del 0.0833 0.6317 Intellectual disability [55]
9q34.11 130497180 130518716 22 29513 3 SH2D3C, TOR2A Amish
specific
59 7 33 Partial gene dup for TOR2A,
gene dup for SH2D3C
0.0116 0.4779
10q11.21 45222200 45359483 125 151274 3 TMEM72-AS1 Rare 38 11 15 Partial gene dup 0.4386 0.5237
10q21.3 68239474 68422442 209 182969 1 CTNNA3 Very rare 19 5 10 Partial gene del 0.6547 0.5957 Arrhythmogenic right
ventricular
cardiomyopathy [56]




46 8 28 Partial gene dup for
MAPK8IP1 and PEX16, gene
dup for C11orf94
0.0197 0.0402 Diabetes type 2 [57],
Zellweger syndrome [58]
11p15.4 8959020 8964938 11 5919 1 ASCL3 Very rare 28 6 12 Gene del 0.4795 0.3681
13q34 112712459 112726336 26 26199 3 SOX1 Amish
specific
109 23 53 Gene dup 0.0254 0.0749 Neuronal development
[59]
13q34 114518789 114530659 31 17552 3 GAS6 Very rare 92 21 45 Partial gene dup 0.6946 0.6193
14q23.2 63957653 63962909 10 6398 1 PPP2R5E Very rare 23 5 12 Intronic del 0.2568 0.1877
15q11.2 24345146 24496990 76 152110 1 PWRN2 Rare 48 20 15 Gene del 0.1967 0.4189 Prader-Willi region [60]
15q26.1 90615898 90636762 28 26809 3 IDH2, ZNF710 Amish
specific
27 8 13 Partial gene dup 0.7389 0.3569 D-2-hydroxyglutaric
aciduria, type II [61]
16p12.1 27337036 27350687 15 20228 0&1 IL4R Very rare 31 9 15 Exonic del 0.7812 0.1062
17p13.3 811982 1183612 665 456481 3 ABR, BHLHA9,
MIR3183, NXN,
TIMM22, TUSC5
Very rare 23 3 12 Partial gene dup for NXN
and TUSC5, gene dup for
ABR, BHLHA9, MIR3183 and
TIMM22
0.6547 0.3319
18q23 77150335 77162816 40 24952 3 NFATC1 Amish
specific
41 13 23 Exonic dup 0.8273 0.1415 Tricuspid atresia [62]
18q23 76725624 76767375 35 41752 3 SALL3 Very rare 37 11 30 Gene dup 0.1336 0.0864
18q23 77241092 77251061 21 16450 3 NFATC1 Amish
specific
31 13 19 Exonic dup 0.3938 0.1313
21q22.3 44822871 44868895 35 46025 3 SIK1 Rare 95 22 38 Gene dup 0.2800 0.5553
CNVs shown are rare in controls (present in fewer than 5% of controls. Rare: <5%, Very rare: <1%, Amish Specific: not found in controls), and common in the Amish (present in more than 5% of individuals). Contained
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CNVs with likely deleterious SNPs on the same and in
trans haplotype. Table 4 lists 26 disease genes with both
a CNV and at least one non-synonymous SNP present in
the same gene in the same individual. Among CNVs in
known disease genes are two rare CNVs at the PARK2
locus: a 63 kb deletion and a 99 kb deletion spanning
the second exon. Although these CNVs do not segregate
with a bipolar disease status, it is notable that 300 kb
distal to the CNV breakpoint, in the neighboring
PARK2 co-regulated gene (PACRG), we previously de-
tected a cluster of SNPs with a family-based association
signal of p-value 2.16x10-6 for the top SNP (rs9365506)
(Additional file 1: Figure S3) [33]. In addition, there are
six individuals who have both an exonic missenseTable 4 Compound heterozygosity - Disease genes with
CNVs and variants in the same individual






ATG7 13 26 Rare
SNTG1 4 2 Common
PTPRD 4 3 Rare




KCNJ6 1 0 Amish
Specific
CCDC50 6 15 Common
DICER1 1 1 Amish
Specific
GALNTL4 1 1 Rare
ATP13A4 9 25 Rare
ERBB4 1 3 Common
MSR1 1 3 Rare
PARK2 1 3 Rare
RHD 2 6 Common
CDH13 0 1 Rare
PRKG1 0 1 Rare
WWOX 3 10 Common
SMARCA2 2 8 Common
CYP2D6 0 3 Rare
TUSC3 3 14 Rare
UGT1A7 0 7 Rare
UGT1A8 0 7 Rare
UGT1A10 0 8 Rare
UGT1A3 0 8 Rare
CTNNA3 0 9 Rare
CACNA1C 0 14 Common
Counts in each column represent the number of individuals with both a CNV
and another variant in the same gene.variant (rs1801582) and a CNV in PARK2. The variant
is located upstream of the CNV and in each individual
is present on a different haplotype from the CNV.
Haplotype analysis of the region shows multiple haplo-
types containing the SNPs from the family-based asso-
ciation analysis, two of which contain the CNVs,
further supporting a proposed clustering of several po-
tential risk alleles (SNPs and CNVs) in a defined
chromosomal region [33].
Also among these variants was a rare 2 kb intronic de-
letion in autophagy related 7 (ATG7), which is present in
46 individuals, out of which 13 have a bipolar phenotype
(13/36, 36.1%; unaffected 25/124, 20.2%). Furthermore,
individuals with this CNV also have a possibly damaging
exonic missense SNP (rs36117895) present on the same
haplotype as the CNV. We also identified a number of
individuals (n = 19, affected 3/6, 50%; unaffected 14/39,
35.9%) with a rare CNV in the intron of tumor suppres-
sor candidate 3 (TUSC3). These individuals carry a SNP
(rs1035972) within the same gene on the same haplotype
as the CNV. Although many of these individuals are ‘un-
affected’ (14 unaffected, 3 affected) within our pedigree,
mutations such as these may contribute to the overall
burden of disease within the Amish population.
Discussion
We recently reported a combined analysis of dense ge-
notypes and whole genome sequence for a large Old
Order Amish pedigree with bipolar disorder. This study
focused on the analysis of missense mutations within
linkage peaks and detected a high degree of genetic het-
erogeneity of mental illness in this family [33]. Here we re-
port results of the analysis of CNVs in the same extended
pedigree. The mean burden per individual and size of
CNVs were similar between our Amish sample and the
European controls. While previous studies of the role of
CNVs as risk alleles for bipolar disorder have been limited,
an increased burden of CNVs in bipolar disorder has been
reported by some [26,27], although these findings are not
consistent [28,29]. We find a trend towards an increased
burden of CNVs in genes in individuals with BP, specific-
ally for CNVs that are rare or moderately frequent in the
general population. While this finding does not reach sig-
nificance, it adds to a body of evidence that suggests that
CNVs may have some as-yet undefined role in BP and
should be investigated accordingly.
We identified 13 CNVs in genes previously associated
with psychiatric and developmental disorders, that are
present at a higher rate in the Amish extended pedigree
than in the control sample. The comparison of the fre-
quency of these structural anomalies in the extended pedi-
gree and in a large control dataset identified disease
associated CNVs that are enriched in this population and
may serve as a starting point for a future “Genotype-first
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complex diseases in this founder population. For example,
rare CNVs were found in SOX1, a transcriptional activator
thought to play a role in neuronal development [59]; and
near GM2A, which is highly expressed in the brain and
can harbor mutations which result in a variant of Tay-
Sachs disease [67]; and SLC6A15, an amino acid trans-
porter expressed highly in the brain and associated with
major depressive disorder [68]. The largest rare, genic de-
letion in our pedigree, encompassing PWRN2 and the sur-
rounding region, was found more frequently in bipolar
individuals within carrier families. PWRN2 lies within a
1.5 Mb section on the long arm of chromosome 15 found
to be deleted in Prader-Willi syndrome, a neurogenetic
disorder with cognitive, behavioral and endocrine pheno-
types [69]. A duplication in the HOXD region on chromo-
some 2 was also present more frequently in bipolar
individuals. The HOXD genes play important roles in
morphogenesis, and deletions in this cluster have been as-
sociated with limb and genital abnormalities [70]. Our
study design allowed us to interrogate a combination of
CNVs and other inherited mutations found within the
same gene in a single individual on the same or opposite
chromosome. Using this method, we identify 26 known
disease genes that contain both a CNV and exonic mis-
sense SNP in one or more individuals. Of these, particular
genes of interest include ATG7, which has been associated
with frontotemporal dementia [71]; TUSC3, a gene associ-
ated with intellectual disability [50]; and PARK2, a gene
associated with Parkinson’s disease [55,72]. Although we
do not provide evidence that these CNVs and SNPs alone
are disease causing in this pedigree, they may contribute
together with other variants within the same chromo-
somal region to the disease risk [33]. In addition, molecu-
lar studies of these reported CNVs would be needed to
determine if they have any effect on the gene. Larger stud-
ies in a non-Amish population are also required to deter-
mine if CNVs at these loci could be of relevance to bipolar
or psychiatric disorder in a general population.
Although clinical information for the large extended
Old Order Amish pedigree is limited to mood disorders,
our genetic data permits the analysis of CNVs in genes
associated with Mendelian diseases. In our initial report
on the analysis of CNVs in the core Amish pedigree (in
50 family members), we provided proof of principle for a
family-based investigation of a combination of structural
variants in the same subject as that could confer risk for
a disease [35]. Our reported trend for an increased bur-
den of disease CNVs in bipolar family members (when
compared to their unaffected relatives) needs to be fur-
ther investigated with a larger sample size, both in the
founder and general population. In many Mendelian dis-
eases, psychiatric and behavioral symptoms are prevalent
[73] and a wide range of medical co-morbidities arecommon in psychiatric disorders [63]. The variants
underlying Mendelian disease are generally highly pene-
trant and less influenced by the environment, while hap-
loinsufficiency or heterozygosity at several Mendelian
disease loci may lead to complex behavioral anomalies
in psychiatric disorders. Moreover, such a burden of risk
alleles could explain the high degree of heritability but
rather complex genetic architecture observed in these
disorders. In other words, we propose that some of the
hidden heritability may reside in gene-by-gene interac-
tions and that the analysis of interactions at bona fide
disease genes may be well powered by focusing on the
impact of genetic variation within these critical classes
of genes.
We have identified over 100 CNVs with a significant
difference in allele frequency between the Amish family
and the control sample. These structural variants add to
an extended list of non-synonymous, likely deleterious
variants that are rare in the 1000 Genomes project data-
set (<2%), but present in 1-30% of BP subjects and their
family members [33]. Owing to the anonymized fashion
in which our study was conducted, it will not be pos-
sible, at this time, to evaluate possible phenotypic conse-
quences of private Amish structural variants, those that
are present in >10% of family members in this pedigree,
but rare or absent in the general population. However,
several ongoing genetics research initiatives involving
the Plain populations [33,34] combined with the clinical
genetics profiling applied in several clinics that serve
these communities, are generating valuable insights that
could potentially allow prevention of disability and dis-
ease. As reported by the Clinic For Special Children and
by colleagues involved in genetic studies in Hutterites,
providing education and offering clinical carrier status
for devastating Mendelian diseases would likely be wel-
comed by members of the founder communities [74,75].
Our study has multiple limitations. First of all, the
analysis is focused on a large extended family and power
is limited for the statistical assessment. Also, it is diffi-
cult to determine if CNVs found to be enriched in the
pedigree are unique to this founder population or to a
cluster of these families, originating primarily from the
Lancaster area (in Pennsylvania). However, the use of a
genetic isolate and a large family structure provided us
with a higher level of genetic and phenotypic homogen-
eity, and permitted the tracing of CNV events within nu-
clear families and across generations. Also, although the
availability of biomaterials through a public cell reposi-
tory represents a major advantage of this collection,
DNA isolated from lymphoblastoid cell lines rather than
blood represents a limitation of our study. Therefore, to
avoid possible cell line artifacts, we excluded all single-
ton CNVs from our analysis and we were not able to ad-
dress the role of de novo CNVs. Other studies have
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were unable to address this area of research. We note
that we utilized CNVs from an eye disease study
(AREDS) as a comparison for our dataset. Although we
were not directly comparing the levels of CNVs between
datasets, a disease free control dataset would have been
more desirable. However, as their primary use was to
identify CNVs that are present in the Amish more fre-
quently than a European population, we believe the
AREDS dataset was adequate for this purpose. Finally,
the CNVs reported here were not experimentally vali-
dated, but due to our ability to show inheritance of the
CNV from parent to child through the pedigree, we con-
sider them to be validated CNVs [76].Conclusions
In summary, we identify a number of CNVs in an Old
Order Amish pedigree segregating BP. Many of the
CNVs found were rare in the general population and
present in a large number of Amish individuals. Some of
the CNVs were found in a higher frequency in individ-
uals with a BP phenotype, and within genes known to
play a role in human development and disease. We con-
clude that these CNVs may be contributing factors in
the phenotypic presentation and heterogeneity of mental
illness in this family.Methods
Sample
The genetic-epidemiologic study of bipolar disorder
among the Old Order Amish in Pennsylvania (The
Amish Study of Major Affective Disorder) has been well
documented [77,78]. Diagnostic methods included struc-
tured interviews (SADS-L) that were conducted with the
patients and close others. In addition, medical records
were obtained following signed, informed consent, these
were abstracted and collated for five members of the
Psychiatric Board who were blind to patient names,
pedigree, address, admission/discharge diagnosis and
treatment. The Psychiatric Board members used strict
Research Diagnostic Criteria (RDC) and the Diagnostic
and Statistical Manual of Mental Disorders, 4th Edition
(DSM-IV) for uniform clinical criteria, and reviewed all
material every few years as a reliability check on diagno-
ses. The majority of affected individuals in the current
pedigree are diagnosed as either BPI, BPII, or Major De-
pressive Disorder (MDD, recurrent) with a few Schizoaf-
fective Disorder, BP Subtype, although there is a wider
spectrum of Major Affective Disorders in the extended
Amish pedigrees. In this study we place individuals into
a number of phenotype categories for analysis: Narrow
(BPI and BPII only), Broad (BPI, BPII and MDDR), and
well (unaffected only).Collection of blood samples followed diagnostic con-
sensus. Lymphoblastoid cell lines were established by
the Coriell Institute of Medical Research (CIMR). Signed
informed consents were obtained to access medical re-
cords for the Amish Study clinicians exclusively to do
diagnostic evaluations and clinical studies. Two forms
were used: a) one with yearly Institutional Review Board
(IRB, University of Miami) approval adhering to special
guidelines because the Amish are defined as a “vulnerable”
population; and b) a second using state approved, medical
record consent forms for specific mental health clinics
and psychiatric hospitals throughout central Pennsylvania.
Collection of blood/tissue samples followed diagnostic
consensus, using two informed consent forms: a) one with
annual Univ. Miami IRB approval defining (with language
appropriate for Old Order Amish) how their cells would
be preserved for medical research on Major Affective Dis-
orders; and, b) the Informed Consent Form required by
the Institute for Medical Research (CIMR), later Coriell -
National Institute for General Medical Sciences (NIGMS)
Human Genetic Cell Repository (HGCR). In addition,
analysis of whole-genome sequence data from consented
individuals in this pedigree was also approved by the IRB
of the Weill Cornell Medical College and the Perelman
School of Medicine at the University of Pennsylvania.
Control subjects
Control subjects were selected from the Age-Related Eye
Disease Study (AREDS) sponsored by the National Insti-
tutes of Health (National Eye Institute). This prospective
study of about 3600 participants follows the clinical course
of age-related macular degeneration (AMD) and age-
related cataract. Participants in this study were required to
be ‘free of any illness or condition that would make long-
term follow-up or compliance with study medications un-
likely or difficult’ and as such are considered ‘well’ for the
purposes of our study of mental illness. In addition, age of
participants recruited to this study was between 55 to
80 years old, beyond the age at which presentation of a bi-
polar phenotype is to be expected. The individuals studied
here were not affected with macular degeneration or cata-
ract at the AREDS baseline examination.
Collection of blood samples for genetic research was
performed following recruitment. Lymphoblastoid cell
lines were established by the Coriell Institute of Medical
Research (CIMR). Genotyping was performed on 2159
AREDS samples using Illumina Omni 2.5 M SNP arrays
at the Center for Inherited Disease Research (CIDR). We
performed rigorous quality control of the raw genotype
calls by applying a series of filters on both markers and
samples using PLINK [79]. The initial dataset contained
2,443,179 SNPs and 2159 samples. The following filters
were applied in sequence; the numbers of markers or sam-
ples excluded is given in parentheses: a) exclude SNPs with
Kember et al. BMC Genetics  (2015) 16:27 Page 12 of 15missing rate > 0.5 (34,066), b) exclude samples with missing
rate > 0.02 (0), c) exclude SNPs with missing rate > 0.02
(41,053), d) exclude SNPs with MAF < 0.02 (863,429),
and e) exclude SNPs deviating from Hardy-Weinberg equi-
librium at p < 1-e6 (34,405). After quality controls we
retained 1,470,226 SNPs and 2159 samples. We subse-
quently performed Multi Dimensional Scaling on a set of ~
500 k overlapping SNPs for all available AREDS genotypes
and 1000 Genomes data. This analysis permitted the selec-
tion of 1897 subjects with European ancestry (Additional
file 1: Figure S1) for further CNV calling and analysis.
Genotyping
Genotyping was performed on 394 samples from the ex-
tended Amish pedigree using Illumina Omni 2.5 M SNP
arrays at the Center for Applied Genomics (Children’s
Hospital of Pennsylvania, Philadelphia, PA). As with the
AREDS data, we performed rigorous quality control of
the raw genotype calls by applying a series of filters on
both markers and samples using PLINK [79], with the
addition of excluding markers based on informative
missingness and individuals/markers based on the men-
del error rate. The initial dataset contained 2,379,855
SNPs and 394 samples. The following filters were ap-
plied in sequence; the numbers of markers or samples
excluded is given in parentheses: a) exclude SNPs with
missing rate > 0.5 (19,435), b) exclude samples with
missing rate > 0.02 (6), c) exclude SNPs with missing
rate > 0.02 (31,678), d) exclude SNPs with MAF < 0.02
(1,018,805), e) exclude SNPs with informative missing-
ness p < 1e-6 (0), f ) exclude SNPs deviating from Hardy-
Weinberg equilibrium at p < 1-e6 (0), g) exclude individ-
uals with >5% Mendelian errors (0) and h) exclude SNPs
with >1% Mendelian errors (1334). After quality controls
we retained 1,309,937 SNPs and 388 samples.
Association analysis for all CNV regions was performed
using two different methods: a) FBAT [40] (Version 2.0.4),
a version of the transmission distortion test adapted for lar-
ger families and b) EMMAX [41] (Version from February
2012), a statistical test for association analysis using mixed
models that accounts for the population structure within
the sample.
Identification of copy number variants (CNVs)
CNVs were called by PennCNV, a previously described
CNV detection algorithm [36], using the GC model
wave adjustment [80]. CNVs were removed if they had a
value > 0.30 standard deviation of LRR (LRRSD), a wavi-
ness factor (WF) value > 0.05, or < 5 SNPs. Regions that
are known to be highly unreliable for CNV calls, such as
immunoglobulin regions and the centromeres/telomeres
of chromosomes were excluded from the analysis (see
Additional file 1: Table S1). Samples that had a total
CNV number greater than 3 SD from the mean, orsamples that showed evidence of aneuploidy, were also
excluded. After quality control we retained a set of
18,986 CNVs in 375 individuals from the Amish sample,
and 77,205 in 1,897 individuals from the AREDS sample.
Inherited CNV regions
From all available Amish samples with genotype data, we
selected 328 individuals that belong to a nuclear family
(parent plus children, 54 parents and 274 children) to as-
certain regions containing inherited CNVs. This method
consists of two stages. First, we establish the CNV region
boundaries from the CNV that has the greatest overlap
with other CNVs in the same genomic region. All CNVs
that overlap 50% with this CNV are considered part of
that CNV region. Second, we trace the inheritance of a
CNV region using the pedigree information. For a CNV
region to be inherited, it must be present in both the child
and at least one parent.
Human disease catalog
The Human Genome Mutation Database (HGMD) cata-
logs known disease associated variants (http://www.hgmd.
org/). Most of the clinical phenotypes in the database are
monogenic diseases. In its most recent release (June 2013)
it contains 141,000 different variants in ~5,700 genes
(“HGMD disease genes”) [81]. We cataloged all CNV re-
gions (detected by the analysis of dense genotypes for the
328 Amish family members) that partially or fully overlap
3457 HGMD disease genes (‘DM’ tag in HGMD).
Whole genome sequencing
Whole genome sequencing (WGS) for 80 Old Order
Amish family members (including 30 parent child trios)
was performed by Complete Genomics Inc. (CGI;
Mountain View, CA) using a sequence-by-ligation
method [82]. Paired-end reads of length 70 bp (35 bp at
each end) were mapped to the National Center for Bio-
technology Information (NCBI) human reference gen-
ome (build 37.2) using a Bayesian mapping pipeline
[83]. Variant calls were performed by CGI using version
2.0.3.1 of their pipeline. False discovery rate estimates
for SNP calls of the CGI platform are 0.2–0.6% [82].
Gene annotations were based on the NCBI build 37.2
seq_gene file contained in a NCBI annotation build.
The variant calls within the WGS were processed using
the cgatools software (version 1.5.0, build 31) made
available by CGI. The listvar tool was used to generate
a master list of the 11.1 M variants present in the 80
Amish samples. The testvar tool was used to determine
presence and absence of each variant within the 80
Amish WGS. Only variants with high variant call scores
(“VQHIGH” tag in the data files) were included. For
further QC measures see [33].
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ing and imputation of variants identified by WGS into
the Omni 2.5 M SNP genotypes using the Genotype Im-
putation Given Inheritance (GIGI) software version 1.02.
GIGI performs imputation of dense genotypes in large
pedigrees based on a sparse panel of framework markers
using a Markov Chain Monte Carlo approach. Overall
performance of our imputation is comparable to the
published report [84]. For a threshold on the genotype
imputation posterior probability of 0.85, we observed
overall concordance of ~0.96 with a call rate of ~0.50
As expected, imputation performance increases for
sub-pedigrees with a higher number of samples with
WGS, i.e. when considering only nuclear families with
WGS samples the performance improves to concord-
ance ~0.99 and call rate ~0.87 [33].Additional file
Additional file 1: Figures and Tables illustrating quality control
measures, and supplementary results including additional CNV
regions found in disease genes and on Chromosome X.Competing interests
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